Premier Invests In Exela To Procure Shortage-Hit Generic Injectables
Participating Premier Health Systems Sign Multi-Year Purchasing Commitments
As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.
You may also be interested in...
Generics Industry At The Forefront In War Against COVID-19 In 2021
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
US FDA Board Formed To Manage Increasingly Complex Pharmaceutical Supply Chain Oversight
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, CDER’s Jacqueline Corrigan-Curay, who will chair the group, tells the Pink Sheet.
Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.